Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FLGT
FLGT logo

FLGT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Fulgent Genetics Inc (FLGT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
18.680
1 Day change
-0.53%
52 Week Range
31.040
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

FLGT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is essentially flat, lacks fresh catalysts, and has mixed-to-weak sentiment from analysts and hedge funds. While options positioning is bullish, the overall setup does not justify an immediate large long-term purchase based on the data provided. If you want a direct answer: do not buy aggressively now; hold and wait for clearer fundamental momentum.

Technical Analysis

The technical picture is neutral to slightly constructive but not strong enough for a buy. Price closed at 18.765, just below the pivot at 18.725, with resistance at 19.607 and 20.152 and support at 17.842 and 17.297. RSI_6 at 58.2 is neutral, suggesting no overbought or oversold edge. MACD histogram is positive at 0.0572 but contracting, which means bullish momentum is fading. Moving averages are converging, consistent with a range-bound setup rather than a breakout trend. The stock’s expected near-term move estimate is modest, pointing to limited immediate upside.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish. The open interest put-call ratio of 0.08 is very low, showing heavy call dominance, and the option volume put-call ratio of 0.4 also leans bullish. Call open interest is 3679 versus put open interest of 309, reinforcing positive sentiment. However, IV rank is only 10.97 and IV percentile is 38.1, so the options market is not signaling a major volatility or event-driven move. In short, derivatives positioning is supportive, but not enough by itself to override the weak broader setup.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • ["Options sentiment is strongly bullish, with calls dominating puts.", "MACD remains positive, showing the trend is not bearish.", "Stock is trading close to pivot support, which can offer a reasonable entry area."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst.", "Piper Sandler cut the price target to $15 from $30 and kept a Neutral rating.", "Hedge funds are selling, with selling up 169.46% over the last quarter.", "No recent insider buying trend.", "No congress trading data available.", "Technical momentum is only neutral and not confirming a strong breakout."]

Financial Performance

No usable latest-quarter financial snapshot was provided due to an error, so I cannot confirm revenue or earnings growth from the supplied data. Because the latest quarter season is missing, there is no reliable financial-growth assessment available here.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst action is negative: Piper Sandler lowered its price target from $30 to $15 after quarterly results and maintained a Neutral rating. This indicates reduced Wall Street confidence in the near-term upside. The pros view is limited support from neutral rating rather than outright bearishness, while the cons view is the sharp target cut and lack of a bullish upgrade trend.

Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
Wall Street analysts forecast FLGT stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 18.780
sliders
Low
30
Averages
32.5
High
35
Current: 18.780
sliders
Low
30
Averages
32.5
High
35
Piper Sandler
Neutral
downgrade
$30 -> $15
AI Analysis
2026-05-05
Reason
Piper Sandler
Price Target
$30 -> $15
AI Analysis
2026-05-05
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Fulgent Genetics to $15 from $30 following quarterly results. The firm keeps a Neutral rating on the shares.
UBS
Buy
downgrade
$35 -> $22
2026-03-02
Reason
UBS
Price Target
$35 -> $22
2026-03-02
downgrade
Buy
Reason
UBS lowered the firm's price target on Fulgent Genetics to $22 from $35 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FLGT
Unlock Now

People Also Watch